Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
Ontology highlight
ABSTRACT: Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6 months) of treatment.
Primary measurements focus on safety and tolerability. These will be recorded in real-time and report the number and severity of adverse events.
Secondary measurements will include efficacy, (measured by response rate with RECIST and overall survival in months) supported by biomarker analysis.
DISEASE(S): Neoplasm Metastasis,Colonic Cancer,Colorectal Cancer,Colorectal Neoplasms,Colon,Metastasis,Colonic Neoplasms
PROVIDER: 2117148 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA